Apr 26, 2021 10:31 AM IST
The nod came following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, it said.
- Jan 07, 2021 05:05 PM IST
The current investment has put the post-money valuation of Biocon Biologics at ~$4.17 billion, said Kiran Mazumdar-Shaw, Executive Chairperson of Biocon
- Nov 24, 2020 12:21 PM IST
If the negotiations fructify— coming two weeks after the Goldman Sachs deal—it would mark the fourth successive investment in the Kiran Mazumdar Shaw-led Biocon unit in 2020.The last fundraise was struck at a valuation of $3.94 billion.
- Nov 07, 2020 04:04 PM IST
As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions
- Aug 03, 2020 12:58 PM IST
Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.
- Jul 31, 2020 12:25 PM IST
The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion
- Jul 21, 2020 11:30 AM IST
The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.
- May 12, 2020 02:10 PM IST
Biocon on Tuesday said its arm Biocon Biologics has received EU Good Manufacturing Practice (GMP) certification for its biologics drug substance facilities in Bengaluru.
- Apr 16, 2020 10:15 AM IST
The inspection was conducted between September 10 and September 19, 2019, a company spokesperson said, adding, Biocon Biologics has responded to the regulator on the eight observations from this inspection, in October last year.
- Jan 07, 2020 09:29 PM IST
Moneycontrol’s Jerome Anthony talks to pharma correspondent Viswanath Pilla to find out why the company has received such a high valuation.
- Jan 07, 2020 08:02 PM IST
Syngene, which was listed in August 2015, raised Rs 550 crore. The IPO was subscribed 32 times. Incidentally, True North was an investor in Syngene before it was listed.
- Jan 06, 2020 04:16 PM IST
Biocon said it would use the proceeds of stake sale for expansion of R&D and manufacturing capabilities.